TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female (of non-child bearing potential) between 18 and 70 years of age with Body Mass Index ≥18 to \<38 kg/m2.~* Chronic HCV genotype 3 infection prior to study enrollment and has never received antiviral treatment for HCV.~* Subject has plasma HCV RNA level \> 10,000 IU/mL at Screening.~* Sexually active males must be sterile, have male partners only, or agree to use two effective forms of birth control for 7 months after stopping study drug.~Exclusion Criteria:~* History of severe, life-threatening or other significant sensitivity to any drug.~* Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human Immunodeficiency virus antibody (HIV Ab).~* Prior therapy for the treatment of HCV.~* Any current or past clinical evidence of cirrhosis.~* Any cause of liver disease other than chronic HCV-infection.~* HCV genotype co-infection with any other HCV genotype.~* Use of contraindicated medications within 2 weeks or 10 half-lives of dosing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ABT-450/r and ABT-530 plus RBV (Type: EXPERIMENTAL): ABT-450/r (150 mg/100 mg) once daily (QD) co-administered with ABT-530 (120 mg) once daily (QD) plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Triglyceride Effects on Blood Flow in the Human Brain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previously completed the Meal and Memory study~* Age 55 and older~* Able to read and understand English~* Able to give informed consent~* Able to undergo MRI and ingest dairy products~Exclusion Criteria:~* Did not screen in the Meal and Memory study~* Allergic to or not able to ingest study ingredient (dairy)~* Metal in body or otherwise unable to lay still for an MRI

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: OTHER): Only one arm of study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of chronic plaque psoriasis for at least 6 months before the first administration of study drug. Duration since diagnosis may be reported by the participant~* Participant has stable moderate to severe plaque psoriasis (body surface area \[BSA\] \>10, Psoriasis Area and Severity Index \[PASI\] \>10, and Dermatology Quality of Life Index \[DLQI\] \>10) with or without psoriatic arthritis at Baseline~* Must be naïve to and candidate for systemic therapy, as assessed by the investigator~* Participant has an inadequate response, intolerance or contraindication to topical psoriasis treatment~Exclusion Criteria:~* Participants with non-plaque forms of psoriasis~* Participant has previously received systemic therapy for psoriasis, whether biologic or non-biologic or photochemotherapy~* Active systemic infection during the last 2 weeks (exception: common cold) prior to screening.~* Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix~* Participant has any condition or contraindication to Fumaderm that would preclude the patient's participation in the present study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Risankizumab (Type: EXPERIMENTAL): Participants randomized to receive open-label risankizumab 150 mg by subcutaneous injection at Weeks 0, 4, and 16.
- Fumaderm (Type: ACTIVE_COMPARATOR): Participants randomized to receive open-label Fumaderm 30 mg administered as a tablet orally once daily from Week 0 to Week 2 and then up to 240 mg, 3 times daily from Week 3 to Week 24 if 90% Improvement in Psoriasis Area and Severity Index (PASI90) is not achieved and if tolerability allows.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of Dienogest for the Treatment of Endometriosis in Chinese Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women between 18 and 45 years of age, inclusive~* Women with endometriosis confirmed by laparoscopy or laparotomy within ten years but no later than 2 weeks before the Screening Visit~* A score of at least 30 on a 100 mm visual analog scale (VAS) for endometriosis-associated pelvic pain at Screening Visit and Baseline Visit~* Good general health (except for findings related to endometriosis, with or without infertility), as evidenced by medical history and complete physical and gynecological examination~* Willingness to use a barrier method of contraception is required~Exclusion Criteria:~* Pregnancy or lactation (less than three months since delivery, abortion, or lactation before start of treatment)~* Wish for pregnancy within intended treatment period~* Before menarche or after menopause~* Amenorrhea (more than three consecutive months in the six months before screening)~* Undiagnosed abnormal genital bleeding~* Previous/use of hormonal agents~* Any disease or condition that may worsen under hormonal treatment~* Signs and/or symptoms of therapy-resistant endometriosis despite more than one prior attempt at drug treatment or surgical therapy~* Need for primary surgical treatment of endometriosis~* Regular use of pain medication due to other underlying diseases~* Contra-indication for the supportive analgesic medication (ibuprofen)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Dienogest (Type: EXPERIMENTAL): 50% of the participants will be randomized to this arm and will receive 2 mg dienogest (DNG) once daily by mouth from 0-52 weeks
- Placebo (Type: PLACEBO_COMPARATOR): 50% of the participants will be randomized to this arm and will receive placebo once daily by mouth from 0-24 weeks then switch to 2 mg dienogest (DNG) once daily by mouth from 25-52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have a 7/8 or 8/8 HLA A, B, C and DR, HLA-matched related donor willing and able to donate allogeneic stem cells.~* For patients with multiple myeloma, CLL, and lymphoma: must be in CR, PR, or stable disease.~* For MDS, acute leukemia or CML: must have \<20% blasts on marrow exam.~* For all other diseases: must have non-refractory disease.~and meet at least ONE of the next three criteria:~* Any patient ≥ 18 years of age with a hematological malignancy and not considered a candidate for allogeneic myeloablative transplant due to illness and/or age (≥55 years).~* Any patient ≥ 18 years of age who has relapsed following prior autologous or allogeneic transplant for a hematologic malignancy.~* Any patient ≥ 18 years of age diagnosed with a hematological malignancy for which reduced intensity transplant is institutionally preferred over myeloablative transplant (eg, chronic lymphocytic leukemia).~Exclusion Criteria:~* Less than 18 years of age.~* Currently taking any HDAC inhibitors, or have taken an HDAC inhibitor within 30 days of the trial.~* Positive serum tests for HIV, HTLV1 / HTLV2.~* Detectable hepatitis B virus (HBV), hepatitis C (HCV) or Epstein-Barr (EBV).~* Pregnancy.~* One or more of the following organ system function criteria~  * Cardiac: Ejection fraction ≤ 40%~ * Renal: Estimated or actual GFR ≤ 40 ml/min (corrected for BSA)~ * Pulmonary: FEV1, FVC, or DLCO ≤ 40% predicted~ * Hepatic: Total bilirubin ≥3 mg% and AST/ALT \>5 x institutional normal for age~ * Karnofsky score ≤50 (Requires considerable assistance and frequent medical care).~* Persistent invasive infections not controlled by antimicrobial medication.~* Any physical or psychological condition that, in the opinion of the investigator, would pose unacceptable risk to the patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vorinostat prophylaxis (Type: EXPERIMENTAL): Vorinostat,combined with standard GVHD prevention medications(tacrolimus, mycophenolate) for adults who received a reduced intensity, related donor stem cell transplant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Unequivocal histologic diagnosis of AML according to World Health Organization (WHO) criteria, EXCLUDING:~  * Acute promyelocytic leukemia t(15;17)(q22;q12); promyelocytic leukemia (PML)-retinoic acid receptor, alpha (RARA)~ * Acute myeloid leukemia with t(8;21)(q22;q22); runt-related transcription factor 1 (RUNX1-RUNXT1) as determined by the Ohio State University (OSU) Molecular Reference Laboratory, per CALGB 20202~ * Acute myeloid leukemia with inv(16)(p13.1;q22) or t(16;16(p13.1;q22); core-binding factor, beta subunit (CBFB)-myosin, heavy chain 11, smooth muscle (MYH11) as determined by the OSU Molecular Reference Laboratory, per CALGB 20202~* AML patients with an antecedent hematologic disorder are eligible for treatment on this trial provided that they have not received chemotherapy, including lenalidomide, azacitidine or decitabine for their hematologic disorder; patients with therapy-related AML are eligible if there had been no further exposure to chemotherapy or radiation therapy for \> 3 years and their primary malignancy is in remission~* FLT3 mutation (ITD or point mutation) determined by the OSU Molecular Reference Laboratory, per CALGB 20202~* No prior chemotherapy for AML with the following exceptions:~  * Emergency leukapheresis~ * Emergency treatment for hyperleukocytosis with hydroxyurea~ * Cranial radiation therapy (RT) for central nervous system (CNS) leukostasis (one dose only)~ * Growth factor/cytokine support~ * All-trans retinoic acid (ATRA)

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (daunorubicin, cytarabine, sorafenib tosylate) (Type: EXPERIMENTAL): INDUCTION THERAPY: Daunorubicin hydrochloride 60 mg/m\^2/day by IV push or short IV on days 1-3, cytarabine 100 mg/m\^2/day by continuous IV on days 1-7, and sorafenib tosylate orally every 12 hours on days 1-7.~CONSOLIDATION THERAPY - Every 28 days for 2 cycles: Cytarabine 2 g/m\^2/day by IV on days 1-5 and sorafenib tosylate 400 mg orally every 12 hours on days 1-28.~MAINTENANCE - Every 28 days for up to 12 cycles: Sorafenib tosylate 400 mg orally every 12 hours on days 1-28.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documentation by MR of a gadolinium-enhancing intraparenchymal mass consistent with malignant glioma.~* Frozen section diagnosis of WHO Grade IV glioma, confirmed with permanent section and immunopositive for IGF-1R.~* An Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 or a Karnofsky Performance Score (KPS) of at least 60.~* Must be 18 years of age or older.~* Must sign an approved informed consent.~* Hemodynamically stable, consistent with Standard of Care values for patients undergoing elective tumor resection.~Exclusion Criteria:~* Females who are pregnant, nursing, or not inclined to use adequate contraceptive methods if necessary to prevent pregnancy during the study.~* An active second primary malignancy with the exception of basal cell or squamous cell skin carcinoma.~* Major concomitant medical illness inclusive of severe chronic obstructive pulmonary disease, multiple sclerosis, symptomatic coronary artery disease, heart failure, recent major cerebrovascular accident, brittle diabetes, renal dialysis, end stage liver disease, labile hypertension, or any autoimmune disorder.~* A history of heparin-induced thrombocytopenia or hypersensitivity to heparin, enoxaparin, or pork products.~* An abnormal International Normalized Ratio (INR) of greater than 1.3, if repeatable and refractory to correction by routine methods.~* Documented deep venous thrombosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): After protocol amendment dated 11 May 2017, all subjects enrolled into the trial will receive 20 chambers for 48 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Triple Therapy With Palonosetron for PON Prophylaxis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, 18 to 85 years of age, of any race or gender. With an American Society of Anesthesiologist (ASA) physical status of I to III who are scheduled to undergo neurological surgery requiring opening of the cranium and Dura matter under general anesthesia, at Ohio State University Medical Center and who consent in writing to participating in this study.~* Post operative hospitalization expected to last at least 72 hours.~* Subjects whose surgery is expected to require at least 1 hours of general anesthesia~* Subjects who have a negative serum or urine pregnancy test within 1 day of surgery or who have been surgically sterilized or are postmenopausal.~Exclusion Criteria:~* Subjects who are prisoners, pregnant, mentally ill, under the age of 18 or over the age of 85, ASA classification of V, alcohol or drug abusers.~* Subjects with known hypersensitivity to any 5-HT3 antagonist, to any agent that is part of the anesthesia regimen, or to other medications to be administered under this protocol.~* Subjects who are breastfeeding.~* Subjects who have had retching/vomiting or moderate to severe nausea in the 24 hours prior to anesthesia or suffer chronic nausea and/or vomiting~* Subjects who have been treated with any drug or other treatment with anti-emetic efficacy within the last 24 hours prior to the start of treatment.~* Subjects who have participated in a clinical trial of an investigational drug within 30 days prior to surgery.~* Subjects who are participating in any other clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Triple therapy PONV prophylaxis (Type: EXPERIMENTAL): At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV and promethazine 25 mg IV was given as PONV prophylaxis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Ultra-low-dose Naloxone on Remifentanil-induced Postoperative Hyperalgesia - A Randomized Controlled Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients who are scheduled to undergo elective thyroidectomy~Exclusion Criteria:~* consent refusal, obesity, pregnancy, hx. of thyroid surgery, neurological disorders, psychiatric disorders, hx. of drug abuse or chronic use of opioids or sedative drugs, intake of any analgesic drug within 12h before surgery.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- group LR (Type: PLACEBO_COMPARATOR): low dose remifentanil (1 ng/ml of Ce) with normal saline infusion
- group HR (Type: ACTIVE_COMPARATOR): High dose remifentanil infusion (4ng/ml of Ce) with normal saline infusion
- group HR-N (Type: EXPERIMENTAL): remifentanil infusion at 4ng/ml of Ce with naloxone infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of a Lipiodol Emulsion for the Embolization of Hypervascularizations in Patients With Knee Pain (LipioJoint1)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary inflammatory knee osteoarthritis of the target joint defined by a knee osteoarthritis according to the American College of Rheumatology (ACR) classification and a score ≥ 2 according to the classification of Kellgren and Lawrence~* Patient not eligible for surgery (or refusing surgery)~* Analog Visual Scale (VAS) pain ≥ 40 mm despite analgesic treatment for at least 3 months~* Failure or intolerance of treatment with NSAIDs and/or tramadol and/or acetaminophen, and/or failure or intolerance or patient refusing strong opioids medication (morphine, codeine)~* Failure or patient refusal of corticosteroid infiltration~* Patient who has signed an informed consent~Exclusion Criteria:~* Patient who is unable or unable to comply with the follow-up schedule~* Infiltration of target joint less than three months old~* Treated hyperthyroidism~* Traumatic injury, hemorrhage or bleeding less than 1 week old in the target joint~* Known arterial disease of the lower limbs stage ≥ 2 according to the classification of Leriche and Fontaine~* Known severe allergy to Lipiodol® and/or iodized contrast product~* Known severe kidney failure (creatinine clearance \< 30 ml/min)~* Pregnant or breastfeeding woman~* Patient not affiliated with a French Medicare~* Patient benefiting from legal protection~* Participation in another interventional research

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Embolization (Type: EXPERIMENTAL): Embolization of the inflammatory hypervascularization with a lipiodol emulsion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* hereditary hemorrhagic telangiectasia with nosebleeds and desire to be treated.~Exclusion Criteria:~* pregnant,~* minor,~* had an increased risk of thrombotic events (history or signs of cerebrovascular events, cardiac arrhythmias, biochemically increased coagulation parameters),~* renal insufficiency,~* a history of massive hematuria or defects of color vision.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I (Type: EXPERIMENTAL): First verum (3 times 1 g Tranexamic acid daily) for three months, than placebo for 3 months.
- Group II (Type: EXPERIMENTAL): First placebo for 3 months, than verum for 3 months (3 times 1 g Tranexamic acid daily).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete